{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T23:31:29Z","timestamp":1786404689356,"version":"build-2736575974"},"reference-count":115,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Neurodegenerative diseases (ND) give rise to significant declines in motor, autonomic, behavioral, and cognitive functions. Of these conditions, Alzheimer\u2019s disease (AD) and Parkinson\u2019s disease (PD) are the most prevalent, impacting over 55 million people worldwide. Given the staggering financial toll on the global economy and their widespread manifestation, NDs represent a critical issue for healthcare systems worldwide. Current treatment options merely seek to provide symptomatic relief or slow the rate of functional decline and remain financially inaccessible to many patients. Indeed, no therapy has yet demonstrated the potential to halt the trajectory of NDs, let alone reverse them. It is now recognized that brain accumulation of pathological variants of AD- or PD-associated proteins (i.e., amyloid-\u03b2, Tau, \u03b1-synuclein) begins years to decades before the onset of clinical symptoms. Accordingly, there is an urgent need to pursue therapies that prevent the neurodegenerative processes associated with pathological protein aggregation long before a clinical diagnosis can be made. These therapies must be safe, convenient, and affordable to ensure broad coverage in at-risk populations. Based on the need to intervene long before clinical symptoms appear, in this review, we present a rationale for greater investment to support the development of active immunotherapy for the prevention of the two most common NDs based on their safety profile, ability to specifically target pathological proteins, as well as the significantly lower costs associated with manufacturing and distribution, which stands to expand accessibility to millions of people globally.<\/jats:p>","DOI":"10.3390\/vaccines12090973","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T03:57:06Z","timestamp":1724817426000},"page":"973","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Active Immunotherapy for the Prevention of Alzheimer\u2019s and Parkinson\u2019s Disease"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7560-359X","authenticated-orcid":false,"given":"Madeline M.","family":"Vroom","sequence":"first","affiliation":[{"name":"Vaxxinity, Inc., Space Life Sciences Lab, 505 Odyssey Way, Merritt Island, FL 32953, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6455-514X","authenticated-orcid":false,"given":"Jean-Cosme","family":"Dodart","sequence":"additional","affiliation":[{"name":"Vaxxinity, Inc., Space Life Sciences Lab, 505 Odyssey Way, Merritt Island, FL 32953, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,28]]},"reference":[{"key":"ref_1","unstructured":"Prince, M., Wimo, A., Guerchet, M., Ali, G.C., Wu, Y.T., and Prina, M. (2015). World Alzheimer Report 2015: The Global Impact of Dementia\u2014An Analysis of Prevalence, Incidence, Cost and Trends, Alzheimer\u2019s Disease International."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"101580","DOI":"10.1016\/j.eclinm.2022.101580","article-title":"Global and regional projections of the economic burden of Alzheimer\u2019s disease and related dementias from 2019 to 2050: A value of statistical life approach","volume":"51","author":"Nandi","year":"2022","journal-title":"eClinicalMedicine"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1002\/alz.12901","article-title":"The worldwide costs of dementia in 2019","volume":"19","author":"Wimo","year":"2023","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_4","unstructured":"Mohandas, E., Rajmohan, V., and Raghunath, B. (2024, July 24). Neurobiology of Alzheimer\u2019s Disease. Available online: http:\/\/www.indianjpsychiatry.org."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Morales, V., Gonz\u00e1lez-Acedo, A., Melguizo-Rodr\u00edguez, L., Pardo-Moreno, T., Costela-Ruiz, V.J., Montiel-Troya, M., and Ramos-Rodr\u00edguez, J.J. (2021). Current understanding of the physiopathology, diagnosis and therapeutic approach to Alzheimer\u2019s disease. Biomedicines, 9.","DOI":"10.3390\/biomedicines9121910"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"712","DOI":"10.2174\/1567205012666150701103107","article-title":"Neurobiology of Alzheimer\u2019s Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions","volume":"12","author":"Raskin","year":"2015","journal-title":"Curr. Alzheimer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"a009258","DOI":"10.1101\/cshperspect.a009258","article-title":"Parkinson\u2019s Disease and Parkinsonism: Neuropathology","volume":"2","author":"Dickson","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/jnnp-2019-322338","article-title":"Parkinson\u2019s disease: Etiopathogenesis and treatment","volume":"91","author":"Jankovic","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s42269-023-01047-4","article-title":"A detailed review of pathophysiology, epidemiology, cellular and molecular pathways involved in the development and prognosis of Parkinson\u2019s disease with insights into screening models","volume":"47","author":"Sayyaed","year":"2023","journal-title":"Bull. Natl. Res. Cent."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41582-019-0244-7","article-title":"Ageing as a risk factor for neurodegenerative disease","volume":"15","author":"Hou","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"ref_11","unstructured":"United Nations (2022). United Nations World Population Prospects 2022, Department of Economic and Social Affairs, Population Division."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00401-020-02196-w","article-title":"The physiological roles of tau and A\u03b2: Implications for Alzheimer\u2019s disease pa-thology and therapeutics","volume":"140","author":"Kent","year":"2020","journal-title":"Acta Neuropathol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","article-title":"The Amyloid-beta Pathway in Alzheimer\u2019s Disease","volume":"26","author":"Hampel","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41419-023-05672-9","article-title":"Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: From overt neurodegeneration back to early synaptic dysfunction","volume":"14","author":"Calabresi","year":"2023","journal-title":"Cell Death Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1126\/science.1195227","article-title":"\u03b1-Synuclein promotes SNARE-complex assembly in vivo and in vitro","volume":"329","author":"Sharma","year":"2010","journal-title":"Science"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"17082","DOI":"10.1016\/S0021-9258(18)41896-0","article-title":"Mass spectrometry of purified amyloid \u03b2 protein in Alzheimer\u2019s disease","volume":"267","author":"Mori","year":"1992","journal-title":"J. Biol. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.biopsych.2020.02.001","article-title":"The \u03b2-Secretase BACE1 in Alzheimer\u2019s Disease","volume":"89","author":"Hampel","year":"2021","journal-title":"Biol. Psychiatry"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Miao, J., Shi, R., Li, L., Chen, F., Zhou, Y., Tung, Y.C., Hu, W., Gong, C.-X., Iqbal, K., and Liu, F. (2019). Pathological Tau from Alzheimer\u2019s Brain Induces Site-Specific Hyperphosphorylation and SDS- and Reducing Agent-Resistant Aggregation of Tau in vivo. Front. Aging Neurosci., 11.","DOI":"10.3389\/fnagi.2019.00034"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s00018-022-04240-2","article-title":"Initiation and progression of \u03b1-synuclein pathology in Parkinson\u2019s disease","volume":"79","author":"Tofaris","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and Biomarker Changes in Dominantly Inherited Alzheimer\u2019s Disease","volume":"367","author":"Bateman","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Pardo-Moreno, T., Garc\u00eda-Morales, V., Suleiman-Martos, S., Rivas-Dom\u00ednguez, A., Mohamed-Mohamed, H., Ramos-Rodr\u00edguez, J.J., Melguizo-Rodr\u00edguez, L., and Gonz\u00e1lez-Acedo, A. (2023). Current Treatments and New, Tentative Therapies for Parkinson\u2019s Disease. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15030770"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"746","DOI":"10.2174\/156720512801322564","article-title":"N-Methyl D-Aspartate (NMDA) Receptor Antagonists and Memantine Treatment for Alzheimer\u2019s Disease, Vascular Dementia and Parkinson\u2019s Disease HHS Public Access","volume":"9","author":"Olivares","year":"2012","journal-title":"Curr. Alzheimer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/occmed\/kqm110","article-title":"Active and passive immunity, vaccine types, excipients and licensing","volume":"57","author":"Baxter","year":"2007","journal-title":"Occup. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-024-02886-y","article-title":"Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson\u2019s disease","volume":"30","author":"Pagano","year":"2024","journal-title":"Nat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s40265-021-01569-z","article-title":"Aducanumab: First Approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Qiao, Y., Chi, Y., Zhang, Q., and Ma, Y. (2023). Safety and efficacy of lecanemab for Alzheimer\u2019s disease: A systematic review and meta-analysis of randomized clinical trials. Front. Aging Neurosci., 15.","DOI":"10.3389\/fnagi.2023.1169499"},{"key":"ref_27","first-page":"142","article-title":"Donanemab in early Alzheimer\u2019s Disease","volume":"22","author":"Riederer","year":"2021","journal-title":"J. Neurol. Neurochir. Psychiatr."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s40265-023-01858-9","article-title":"Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer\u2019s Disease Ther-apeutics","volume":"83","author":"Cummings","year":"2023","journal-title":"Drugs"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13195-024-01412-z","article-title":"The search for clarity regarding \u201cclinically meaningful outcomes\u201d in Alzheimer disease clinical trials: CLARITY-AD and Beyond","volume":"16","author":"Tarawneh","year":"2024","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Wojtunik-Kulesza, K., Rudkowska, M., and Orze\u0142-Sajd\u0142owska, A. (2023). Aducanumab\u2014Hope or Disappointment for Alzheimer\u2019s Disease. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054367"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1056\/NEJMp2110468","article-title":"Revisiting FDA Approval of Aducanumab","volume":"385","author":"Alexander","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","article-title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Reiss, A.B., Muhieddine, D., Jacob, B., Mesbah, M., Pinkhasov, A., Gomolin, I.H., Stecker, M.M., Wisniewski, T., and De Leon, J. (2023). Alzheimer\u2019s Disease Treatment: The Search for a Breakthrough. Medicina, 59.","DOI":"10.3390\/medicina59061084"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","article-title":"Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: A prespecified analysis of the FOURIER randomised controlled trial","volume":"5","author":"Sabatine","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: A prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.lungcan.2023.01.006","article-title":"Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis","volume":"177","author":"Popoff","year":"2023","journal-title":"Lung Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Lu, X., Hu, R., Peng, L., Liu, M., and Sun, Z. (2021). Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.638444"},{"key":"ref_39","first-page":"595","article-title":"\u2018Time Saved\u2019 As a Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings","volume":"10","author":"Dickson","year":"2023","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s12967-024-05248-x","article-title":"Passive immunotherapy for Alzheimer\u2019s disease: Challenges & future directions","volume":"22","author":"Yi","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/09727531221136349","article-title":"Future of Monoclonal Antibody Therapy in Parkinson\u2019s Disease","volume":"30","author":"Kharel","year":"2023","journal-title":"Ann. Neurosci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"100982","DOI":"10.1016\/j.xcrm.2023.100982","article-title":"Lecanemab reduces brain amyloid-\u03b2 and delays cognitive worsening","volume":"4","author":"Knopman","year":"2023","journal-title":"Cell Rep. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"108870","DOI":"10.1016\/j.neuropharm.2021.108870","article-title":"Targeting alpha-synuclein via the immune system in Parkinson\u2019s disease: Current vaccine therapies","volume":"202","author":"Fleming","year":"2022","journal-title":"Neuropharmacology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1136\/jnnp-2015-311890","article-title":"The prediagnostic phase of Parkinson\u2019s disease","volume":"87","author":"Noyce","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Fan, J., Jin, S., Gilmartin, L., Toth, I., Hussein, W.M., and Stephenson, R.J. (2022). Advances in Infectious Disease Vaccine Adjuvants. Vaccines, 10.","DOI":"10.3390\/vaccines10071120"},{"key":"ref_46","first-page":"e16635","article-title":"Vaccine Development Throughout History","volume":"13","author":"Saleh","year":"2021","journal-title":"Cureus"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1017\/mdh.2019.77","article-title":"Re-assessing the Foundations: Worldwide smallpox eradication, 1957\u20131967","volume":"64","author":"Bhattacharya","year":"2020","journal-title":"Med. Hist."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Tian, Y., Hu, D., Li, Y., and Yang, L. (2022). Development of therapeutic vaccines for the treatment of diseases. Mol. Biomed., 3.","DOI":"10.1186\/s43556-022-00098-9"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.provac.2011.10.010","article-title":"U.S. FDA requirements for Human Vaccine Product Safety and Potency Testing","volume":"5","author":"Finn","year":"2011","journal-title":"Procedia Vaccinol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e209218","DOI":"10.1212\/WNL.0000000000209218","article-title":"Cost-Effectiveness of Lecanemab for Individuals with Early-Stage Alzheimer Disease","volume":"102","author":"Nguyen","year":"2024","journal-title":"Neurology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1021\/acs.molpharmaceut.3c00440","article-title":"Biophysical Determinants for the Viscosity of Concentrated Monoclonal Antibody Solutions","volume":"20","author":"Mosca","year":"2023","journal-title":"Mol. Pharm."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1586\/14760584.2015.1081067","article-title":"Effect of vaccine administration modality on immunogenicity and efficacy","volume":"14","author":"Zhang","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(08)60839-9","article-title":"Use of a patch containing heat-labile toxin from Escherichia coli against travellers\u2019 diarrhoea: A phase II, randomised, double-blind, placebo-controlled field trial","volume":"371","author":"Frech","year":"2008","journal-title":"Lancet"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"6891","DOI":"10.1016\/j.vaccine.2007.07.014","article-title":"Safety and efficacy of transcutaneous vaccination using a patch with the live-attenuated measles vaccine in humans","volume":"25","author":"Etchart","year":"2007","journal-title":"Vaccine"},{"key":"ref_55","first-page":"11","article-title":"Therapeutic vaccines for nicotine dependence","volume":"8","author":"Maurer","year":"2006","journal-title":"Curr. Opin. Mol. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1016\/j.vaccine.2019.03.035","article-title":"Potential use of microarray patches for vaccine delivery in low- and middle- income countries","volume":"37","author":"Peyraud","year":"2019","journal-title":"Vaccine"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s40274-019-6356-x","article-title":"Bivalent HPV vaccine cost effective at Gavi prices in Bangladesh","volume":"841","author":"Mahumud","year":"2019","journal-title":"PharmacoEcon Outcomes News"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"501","DOI":"10.4161\/hv.18862","article-title":"Rotavirus vaccine: A cost effective control measure for India","volume":"8","author":"Kumar","year":"2012","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1016\/j.vaccine.2019.04.016","article-title":"Apples and oranges? Can second generation vaccines become as low cost as generic medicines?","volume":"37","author":"Nguyen","year":"2019","journal-title":"Vaccine"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Nimmo, J.T., Kelly, L., Verma, A., Carare, R.O., Nicoll, J.A.R., and Dodart, J.-C. (2021). Amyloid-\u03b2 and \u03b1-Synuclein Immunotherapy: From Experimental Studies to Clinical Trials. Front. Neurosci., 15.","DOI":"10.3389\/fnins.2021.733857"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2174\/1876326X01206010064","article-title":"Balancing the efficacy and safety of vaccines in the elderly","volume":"6","author":"Amanna","year":"2012","journal-title":"Open Longev. Sci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/415462a","article-title":"Nerve inflammation halts trial for Alzheimer\u2019s drug","volume":"415","author":"Check","year":"2002","journal-title":"Nature"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.neurobiolaging.2003.12.020","article-title":"Lessons from the AN 1792 Alzheimer vaccine: Lest we forget","volume":"25","author":"Robinson","year":"2004","journal-title":"Neurobiol. Aging"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/jnc.13608","article-title":"A retrospective analysis of the Alzheimer\u2019s disease vaccine progress\u2014The critical need for new development strategies","volume":"137","author":"Marciani","year":"2016","journal-title":"J. Neurochem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.drudis.2014.02.015","article-title":"New Th2 adjuvants for preventive and active immunotherapy of neurodegenerative proteinopathies","volume":"19","author":"Marciani","year":"2014","journal-title":"Drug Discov. Today"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.intimp.2015.10.028","article-title":"Is fucose the answer to the immunomodulatory paradox of Quillaja saponins?","volume":"29","author":"Marciani","year":"2015","journal-title":"Int. Immunopharmacol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(08)70170-4","article-title":"Amyloid-\u03b2 immunisation for Alzheimer\u2019s disease","volume":"7","author":"Wisniewski","year":"2008","journal-title":"Lancet Neurol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"fcac022","DOI":"10.1093\/braincomms\/fcac022","article-title":"An amyloid beta vaccine that safely drives immunity to a key pathological species in Alzheimer\u2019s disease: Pyroglutamate amyloid beta","volume":"4","author":"Vukicevic","year":"2022","journal-title":"Brain Commun."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1567-5769(01)00016-9","article-title":"Altered immunomodulating and toxicological properties of degraded Quillaja saponaria Molina saponins","volume":"1","author":"Marciani","year":"2001","journal-title":"Int. Immunopharmacol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41581-023-00720-1","article-title":"Pathogenesis of autoimmune disease","volume":"19","author":"Pisetsky","year":"2023","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s12016-010-8242-y","article-title":"Immunology, autoimmunity, and autoantibodies in parkinson\u2019s disease","volume":"42","author":"Benkler","year":"2011","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_72","first-page":"51","article-title":"Detection of Alzheimer\u2019s disease at mild cognitive impairment and disease progression using autoan-tibodies as blood-based biomarkers","volume":"3","author":"DeMarshall","year":"2016","journal-title":"Alzheimer\u2019s Dement. Diagn. Assess. Dis. Monit."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jneuroim.2015.08.008","article-title":"Alzheimer\u2019s disease vaccine development: A new strategy focusing on immune modulation","volume":"287","author":"Marciani","year":"2015","journal-title":"J. Neuroimmunol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/21645515.2019.1665453","article-title":"Rationale for the development of an Alzheimer\u2019s disease vaccine","volume":"16","author":"Kwan","year":"2020","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Mortada, I., Farah, R., Nabha, S., Ojcius, D.M., Fares, Y., Almawi, W.Y., and Sadier, N.S. (2021). Immunotherapies for Neurodegenerative Diseases. Front. Neurol., 12.","DOI":"10.3389\/fneur.2021.654739"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1590\/1414-431X20143434","article-title":"Alzheimer\u2019s disease: Is a vaccine possible?","volume":"47","author":"Yang","year":"2014","journal-title":"Braz. J. Med. Biol. Res."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Monroy, G.R., Murguiondo P\u00e9rez, R., Weintraub Ben Zi\u00f3n, E., Vidal Alc\u00e1ntar-Garibay, O., Loza-L\u00f3pez, E.C., Tejerina Marion, E., Blancarte Hern\u00e1ndez, E., Navarro-Torres, L., and Ibarra, A. (2023). Immunization with Neural-Derived Peptides in Neurodegenerative Diseases: A Narrative Review. Biomedicines, 11.","DOI":"10.3390\/biomedicines11030919"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Yu, H.J., Dickson, S.P., Wang, P.N., Chiu, M.J., Huang, C.C., Chang, C.C., Liu, H., Hendrix, S.B., Dodart, J.C., and Verma, A. (2023). Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer\u2019s disease: A randomised, double-blind, placebo-controlled, phase 2a study. EBioMedicine, 94.","DOI":"10.1016\/j.ebiom.2023.104665"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1002\/alz.13532","article-title":"Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque depo-sition in cognitively unimpaired APOE \u03b54 homozygotes","volume":"20","author":"Riviere","year":"2024","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2174\/1567205014666170117101537","article-title":"Long-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer\u2019s Disease","volume":"14","author":"Hull","year":"2017","journal-title":"Curr. Alzheimer Res."},{"key":"ref_81","unstructured":"(2024, July 24). H. Lundbeck A\/S. Study to Evaluate the Safety and Tolerability of a New Drug Named Lu AF20513 in Patients with Mild Alzheimer\u2019s Disease, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02388152."},{"key":"ref_82","unstructured":"(2024, July 24). H. Lundbeck A\/S. A Study to Evaluate the Long-Term Safety and Tolerability of Lu AF20513 and the Antibody Response in Patients with Alzheimer\u2019s Disease (AD), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03668405."},{"key":"ref_83","unstructured":"(2024, July 24). H. Lundbeck A\/S. Study with Lu AF20513 in Patients with Mild Alzheimer\u2019s Disease (AD) or Mild Cognitive Impairment (MCI) Due to AD, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03819699."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.trci.2017.03.005","article-title":"UB-311, a novel UBITh\u00ae amyloid \u03b2 peptide vaccine for mild Alzheimer\u2019s disease","volume":"3","author":"Wang","year":"2017","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1001\/jamaneurol.2022.0983","article-title":"Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults with Down Syndrome: A Phase 1b Randomized Clinical Trial","volume":"79","author":"Rafii","year":"2022","journal-title":"JAMA Neurol."},{"key":"ref_86","unstructured":"Merck Sharp & Dohme LLC (2024, July 24). A Study of V950 in People with Alzheimer Disease (V950-001 AM7), Available online: https:\/\/clinicaltrials.gov\/study\/NCT00464334?term=v950&rank=1."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e082952","DOI":"10.1002\/alz.082952","article-title":"AB1601 Phase 2 Study of ABvac40, an Anti-A\u03b240 Vaccine: Safety and Immunogenicity of a Cross-Over Extension","volume":"19","author":"Lacosta","year":"2023","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"S793","DOI":"10.1016\/j.jalz.2011.05.2274","article-title":"P4-249: Development of AFFITOPE Alzheimer vaccines: Results of phase I studies with AD01 and AD02","volume":"7","author":"Mandler","year":"2011","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_89","first-page":"103","article-title":"Results from a Phase II Study to Assess the Clinical and Immunological Activity of AFFITOPE\u00ae AD02 in Patients with Early Alzheimer\u2019s Disease","volume":"2","author":"Schneeberger","year":"2015","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s43587-021-00070-2","article-title":"ADAMANT: A placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer\u2019s disease","volume":"1","author":"Novak","year":"2021","journal-title":"Nat. Aging"},{"key":"ref_91","unstructured":"AC Immune (2024, July 24). PRESS RELEASE: AC Immune\u2019s Alzheimer\u2019s Vaccine Generates Potent Anti-PTau Antibody Response in a Phase 1b\/2a Study. Available online: https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immunes-alzheimers-vaccine-generates-potent-anti-ptau."},{"key":"ref_92","first-page":"5","article-title":"Clinical trial highlights: Targeting alpha-synuclein","volume":"9","author":"McFarthing","year":"2019","journal-title":"J. Park. Dis."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Eijsvogel, P., Misra, P., Concha-Marambio, L., Boyd, J.D., Ding, S., Fedor, L., Hsieh, Y.-T., Sun, Y.S., Vroom, M.M., and Farris, C.M. (2024). Target engagement and immunogenicity of an active immunotherapeutic targeting pathological \u03b1-synuclein: A phase 1 placebo-controlled trial. Nat. Med.","DOI":"10.1038\/s41591-024-03101-8"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.2217\/imt-2016-0019","article-title":"Tau-based therapeutics for alzheimer\u2019s disease: Active and passive immunotherapy","volume":"8","author":"Panza","year":"2016","journal-title":"Immunotherapy"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Rudan Njavro, J., Vukicevic, M., Fiorini, E., Dinkel, L., M\u00fcller, S.A., Berghofer, A., Bordier, C., Kozlov, S., Halle, A., and Buschmann, K. (2023). Beneficial Effect of ACI-24 Vaccination on A\u03b2 Plaque Pathology and Microglial Phenotypes in an Am-yloidosis Mouse Model. Cells, 12.","DOI":"10.3390\/cells12010079"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"P447","DOI":"10.1016\/j.jalz.2014.05.606","article-title":"P1-364: Active AB Immunotherapy Cad106 Phase II Dose-Adjuvant Finding Study: IM-Mune Response","volume":"10","author":"Riviere","year":"2014","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"841","DOI":"10.2119\/molmed.2016.00218","article-title":"A modification-specific peptide-based immunization approach using CRM197 carrier protein: Development of a selective vaccine against pyroglutamate A\u03b2 peptides","volume":"22","author":"Vingtdeux","year":"2016","journal-title":"Mol. Med."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Vassilakopoulou, V., Karachaliou, C.-E., Evangelou, A., Zikos, C., and Livaniou, E. (2021). Peptide-based vaccines for neurodegenerative diseases: Recent endeavors and future perspectives. Vaccines, 9.","DOI":"10.3390\/vaccines9111278"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.neurobiolaging.2012.01.088","article-title":"70 AFFITOPE\u00ae\u2014Based vaccines: Results from phase I support the further clinical development of AFFITOPE\u00ae AD02","volume":"33","author":"Schneeberger","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/PL00022910","article-title":"Preclinical (premotor) Parkinson\u2019s disease","volume":"247","author":"Wolters","year":"2000","journal-title":"J. Neurol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of alzheimer\u2019s disease: Recommendations from the national institute on aging-alzheimer\u2019s association workgroups on diagnostic guidelines for alzheimer\u2019s disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"101","DOI":"10.31887\/DCNS.2003.5.1\/hhippius","article-title":"The discovery of Alzheimer\u2019s disease","volume":"5","author":"Hippius","year":"2003","journal-title":"Dialogues Clin. Neurosci."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"a008862","DOI":"10.1101\/cshperspect.a008862","article-title":"The history of parkinson\u2019s disease: Early clinical descriptions and neurological therapies","volume":"1","author":"Goetz","year":"2011","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1002\/alz.12756","article-title":"The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease","volume":"18","author":"Hansson","year":"2022","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s10020-021-00327-x","article-title":"Circuit imaging biomarkers in preclinical and prodromal Parkinson\u2019s disease","volume":"27","author":"Meles","year":"2021","journal-title":"Mol. Med."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Papaliagkas, V., Kalinderi, K., Vareltzis, P., Moraitou, D., Papamitsou, T., and Chatzidimitriou, M. (2023). CSF Biomarkers in the Early Diagnosis of Mild Cognitive Impairment and Alzheimer\u2019s Disease. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24108976"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"4498","DOI":"10.1002\/alz.12557","article-title":"Association between CSF biomarkers of Alzheimer\u2019s disease and neuropsychiatric symptoms: Mayo Clinic Study of Aging","volume":"19","author":"Rakusa","year":"2023","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Kwon, E.H., Tennagels, S., Gold, R., Gerwert, K., Beyer, L., and T\u00f6nges, L. (2022). Update on CSF Biomarkers in Parkinson\u2019s Disease. Biomolecules, 12.","DOI":"10.3390\/biom12020329"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40035-022-00296-z","article-title":"Advances in the development of new biomarkers for Alzheimer\u2019s disease","volume":"11","author":"Klyucherev","year":"2022","journal-title":"Transl. Neurodegener."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"He, R., Yan, X., Guo, J., Xu, Q., Tang, B., and Sun, Q. (2018). Recent advances in biomarkers for Parkinson\u2019s disease. Front. Aging Neurosci., 10.","DOI":"10.3389\/fnagi.2018.00305"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Aus\u00f3, E., G\u00f3mez-Vicente, V., and Esquiva, G. (2020). Biomarkers for alzheimer\u2019s disease early diagnosis. J. Pers. Med., 10.","DOI":"10.3390\/jpm10030114"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.neurol.2022.09.003","article-title":"Overview of the blood biomarkers in Alzheimer\u2019s disease: Promises and challenges","volume":"179","author":"Delaby","year":"2023","journal-title":"Rev. Neurol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/bcpt.14042","article-title":"Biomarkers of Parkinson\u2019s disease in perspective of early diagnosis and translation of neurotrophic therapies","volume":"135","author":"Tuominen","year":"2024","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","article-title":"Blood biomarkers for Alzheimer\u2019s disease in clinical practice and trials","volume":"3","author":"Hansson","year":"2023","journal-title":"Nat. Aging"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/alz.12301","article-title":"Plasma p-tau181, p-tau217, and other blood-based Alzheimer\u2019s disease biomarkers in a multi-ethnic, community study","volume":"17","author":"Brickman","year":"2021","journal-title":"Alzheimer\u2019s Dement."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/9\/973\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:43:54Z","timestamp":1760111034000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/9\/973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,28]]},"references-count":115,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["vaccines12090973"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12090973","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,28]]}}}